Judith Silverman, Ebrima Gibbs, Xubiao Peng, and others have published results in ACS Neuroscience (published online April 4, 2018) showing the generation of monoclonal antibodies to six specific epitopes on amyloid-ß oligomers (AbO). The authors analyzed the sequence and cyclical conformation of the epitope labeled cSNK, which is found on AbOs present in brain tissue and cerebrospinal fluid (CSF) from patients with Alzheimer's disease (AD). They have developed a monoclonal antibody (mAb) directed against this target that selectively binds AbO, with virtually no off-target binding to non-toxic Ab monomers and fibrils. The mAb, PMN300, also blocked AbO neurotoxicity and propagation in both in vitro and in vivo settings.
Commenting on the announcement, ProMIS President and CEO, Dr. Elliot Goldstein, stated: "This publication describes in detail the first of six distinct therapeutic targets on toxic AbO identified by the ProMIS scientific team. Monoclonal antibodies directed against each of these six targets have been generated. ProMIS now has lead and backup antibodies addressing what we believe to be the full complement of potential targets on toxic AbO, the latter considered to be a root cause of Alzheimer's disease."Next Story